Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
Recombinant interleukin 4 (rIL4) inhibited the proliferation and induction of lymphokine activated killer (LAK) cells in human peripheral blood mononuclear cells (PBMC) cultured in recombinant interleukin 2 (rIL2). Other recombinant cytokines, such as rIFN gamma, rTNF alpha, rIL1, and rIL3, did not inhibit LAK cell induction. rIL4-mediated suppression was dose dependent. As little as 1 U/ml of rIL4 significantly decreased both LAK activity and proliferation of cells induced by incubation of PBMC with 200 U/ml rIL2. Suppression was specific for the induction phase of LAK activity, because rIL4 did not suppress the cytotoxic capability of previously activated LAK cells. rIL4 directly suppressed rIL2-induced activation of precursors into LAK cells, since it inhibited both rIL2-induced proliferation and LAK cell activity in LGL-enriched cell fractions or in purified CD16+ NK cells. Suppressive effects of rIL4 were overcome by adding rIFN gamma to the culture. These results suggest that rIL4 is a potent inhibitor of rIL2-induced activation of PBL, and that the net LAK response in the host may be a function of the production of IL-2, IL-4 and rIFN gamma.
Han
X
X
Capital Institute of Medicine, Beijing, China.
Itoh
K
K
Balch
C M
CM
Pellis
N R
NR
D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D015847:Interleukin-4; D007378:Interleukins / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects; D008213:Lymphocyte Activation; D008545:Melanoma / Q000097:blood; D011994:Recombinant Proteins / Q000494:pharmacology; D012878:Skin Neoplasms / Q000097:blood
D007376:Interleukin-2; D007378:Interleukins; D011994:Recombinant Proteins; D015847:Interleukin-4